Safety of peginterferon in the treatment of chronic hepatitis C.

Publication/Presentation Date

11-1-2008

Abstract

BACKGROUND: Combination of 'pegylated' interferons (IFNs) plus ribavirin, the standard treatment of chronic hepatitis C (CHC), is frequently associated with side effects. Anticipation, recognition and proper management of these side effects are important to ensure compliance with therapy and achievement of sustained virologic response.

OBJECTIVE: To illustrate the side effect profile of pegIFN-alpha in the treatment of CHC.

METHODS: Studies and abstracts were identified through a computerized, English language literature search. Key search terms included peginterferon and CHC. Information available only in abstract form was retrieved from national and international hepatology associations.

RESULTS: Most adverse events occurring with combination therapy can be anticipated and managed appropriately; therefore, premature discontinuation of therapy owing to side effects is not required in most patients.

Volume

7

Issue

6

First Page

771

Last Page

781

ISSN

1744-764X

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

18983223

Department(s)

Administration and Leadership

Document Type

Article

Link to Full Text

Share

COinS